Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Multiple Myeloma (RRMM)”

148 trials

Showing 20 of 148 results

Early research (Phase 1)Ended earlyNCT04272775
What this trial is testing

MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 14
Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Early research (Phase 1)Study completedNCT03650491
What this trial is testing

FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission
Fortis Therapeutics, Inc. 31
Not applicableStudy completedNCT03353545
What this trial is testing

Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions

Who this might be right for
Relapse/Refractory Multiple Myeloma
Genesis Pharma S.A. 110
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Not applicableStudy completedNCT05673967
What this trial is testing

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals 62
Large-scale testing (Phase 3)Active Not RecruitingNCT04939142
What this trial is testing

Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Antengene Corporation 150
Early research (Phase 1)Study completedNCT02283775
What this trial is testing

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 54
Testing effectiveness (Phase 2)Study completedNCT05064358
What this trial is testing

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 177
Testing effectiveness (Phase 2)Ended earlyNCT03481556
What this trial is testing

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Who this might be right for
Multiple Myeloma
Oncopeptides AB 56
Testing effectiveness (Phase 2)Looking for participantsNCT06645678
What this trial is testing

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
YOUNGIL KOH 75
Not applicableNot Yet RecruitingNCT07320326
What this trial is testing

ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Who this might be right for
TCE-RRMM
Peking University People's Hospital 159
Early research (Phase 1)Looking for participantsNCT03110822
What this trial is testing

Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 134
Testing effectiveness (Phase 2)Looking for participantsNCT07227311
What this trial is testing

Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 200
Testing effectiveness (Phase 2)Study completedNCT03136653
What this trial is testing

Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Molecular Partners AG 33
Testing effectiveness (Phase 2)Study completedNCT02045017
What this trial is testing

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Who this might be right for
Multiple Myeloma
Celgene 81
Very early researchNot Yet RecruitingNCT07234721
What this trial is testing

SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 9
Early research (Phase 1)WithdrawnNCT04392648
What this trial is testing

Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D LLC
Testing effectiveness (Phase 2)Ended earlyNCT06655818
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline 4
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation